Compare LAC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAC | NVCR |
|---|---|---|
| Founded | 2023 | 2000 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2023 | 2015 |
| Metric | LAC | NVCR |
|---|---|---|
| Price | $5.03 | $11.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $6.17 | ★ $27.75 |
| AVG Volume (30 Days) | ★ 11.3M | 2.2M |
| Earning Date | 01-01-0001 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $605,220,000.00 |
| Revenue This Year | N/A | $10.50 |
| Revenue Next Year | N/A | $4.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.82 |
| 52 Week Low | $2.31 | $9.82 |
| 52 Week High | $10.52 | $22.29 |
| Indicator | LAC | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 44.15 |
| Support Level | $4.37 | $10.86 |
| Resistance Level | $5.43 | $13.78 |
| Average True Range (ATR) | 0.27 | 0.86 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 47.19 | 25.83 |
Lithium Americas is a pure-play lithium producer. Following a deal with the US government, the firm will own 59% of one resource, Thacker Pass, which is located in northwest Nevada, with automaker General Motors owning 36% and the US government owning 5%. Thacker Pass is under construction and expected to begin production in 2028. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.